Document is current
Any future updates will be listed below
-
Authors
Zhu, Qian https://orcid.org/0000-0001-7062-8221
Balasubramanian, Akhila
Asirvatham, Jaya Ruth
Chatterjee, Megha https://orcid.org/0009-0008-8987-7250
Piyarathna, Badrajee
Kaur, Jaspreet
Mohamed, Nada
Wu, Ling https://orcid.org/0000-0002-5786-4315
Wang, Stacy
Pourfarrokh, Niloufar
Binsol, Paula Danika
Bhargava, Mahak https://orcid.org/0000-0002-9495-9647
Rasaily, Uttam
Xu, Yitian
Zheng, Junjun
Jebakumar, Deborah
Rao, Arundhati
Gutierrez, Carolina https://orcid.org/0000-0002-2941-3461
Omilian, Angela R.
Morrison, Carl
Das, Gokul M. https://orcid.org/0000-0003-2937-8093
Ambrosone, Christine https://orcid.org/0000-0003-1717-9943
Seeley, Erin H.
Chen, Shu-hsia
Li, Yi https://orcid.org/0000-0002-9976-518X
Chang, Eric https://orcid.org/0000-0002-1375-5088
Li, Xiaoxian https://orcid.org/0000-0002-0995-1721
Baker, Elizabeth
Aneja, Ritu
Zhang, Xiang H.-F. https://orcid.org/0000-0002-5674-8670
Sreekumar, Arun https://orcid.org/0000-0001-8956-3675
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 6 June 2025
First Online: 17 July 2025
Competing interests
: Jaya Ruth Asirvatham served as an advisor for Roche. Xiaoxian Li has served as an advisor for AstraZeneca, Roche, Eli Lilly, and Onviv, and Champions Oncology has funded research in Xiaoxian Li’s lab. Dr. Sreekumar reports grants from the Agilent Foundation, non-financial support from Sri Sathya Sai Institute for Higher Learning, India, and personal fees from Karkinos Health Care Pvt. Ltd., India, outside the submitted work. The remaining authors declare no competing interests.
